Article metrics

Download PDFPDF

Original article
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

 

Online download statistics by month:

Online download statistics by month: September 2018 to July 2020

AbstractFullPdf
Sep 201822522588
Oct 201821121149
Nov 2018858529
Dec 2018808034
Jan 2019888816
Feb 2019898833
Mar 2019797829
Apr 2019666322
May 2019615825
Jun 2019707021
Jul 2019767733
Aug 2019787830
Sep 2019797827
Oct 2019787817
Nov 2019414114
Dec 201933328
Jan 202036369
Feb 2020414114
Mar 202029298
Apr 2020444414
May 202029299
Jun 2020252616
Jul 2020333211
Total16761667556